Clinical Trial

Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults

Study acronym: RE-UNITE AD
Recruiting
View on ClinicalTrials.gov →
Summary
The main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at Month 6.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-05-16; most recent amendment 2026-03-11.
Status change: Not Yet Recruiting → Recruiting 2025-07-15
Trial Details
NCT Number NCT06988605
Lead Sponsor Galderma R&D
Conditions Atopic Dermatitis
Enrollment 1,000 participants
Start Date 2025-07-14
Primary Completion 2026-11-06 (estimated)
Study Completion 2027-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-13